Latest News and Press Releases

LOS ANGELES, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The 2024 Beauty Innovation Awards today announced Exoceuticals®, a pioneering skin and hair care company at the forefront of regenerative and...

Bangkok, Nov. 14, 2024 (GLOBE NEWSWIRE) -- At the In-Cosmetics Asia trade show held from Nov. 5 to 7, 2024, Bloomage was awarded the Silver Award in the Spotlight On Formulation category for its...

New York, USA, Jan. 17, 2023 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global dental equipment market is envisioned to garner a revenue of $15,471.7 million and grow...

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...

HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Planning Underway for Next Clinical Study in U.S. SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:...

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...

Phase 1/2 Trial Initiation for Knee Cartilage Regeneration Anticipated in First Quarter 2021 $2M Grant Awarded by the Department of Defense in September 2020 to Support Clinical Development SAN...

HST-001 Demonstrated Separation from Placebo at Week 18 Primary Efficacy Endpoint Assessment HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Week 26 Final Study Results...